Sugi Predict

Sugi Predict / Compounds / SCHEMBL3025580

SCHEMBL3025580

SCHEMBL3025580

COC(=O)c1ccc(N2CCN(C(=O)O)CC2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.63
▸ MAPT P10636 6/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ NPC1 O15118 3/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ TSHR P16473 3/20 0.53
▸ HTT P42858 2/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ HPGD P15428 1/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ MGLL Q99685 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ MEN1 O00255 1/20 0.48
▸ GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6132284 0.95 ALDH1A1 (0.58) ALDH1A1MAPTKMT2ANPC1RAB9A
SCHEMBL64400 0.94 ALDH1A1 (0.57) ALDH1A1MAPTKMT2ANPC1RAB9A
SCHEMBL63698 0.87 MAPT (0.63) ALDH1A1MAPTKMT2ANPC1RAB9A
SCHEMBL12306044 0.86 ALDH1A1 (0.61) ALDH1A1MAPTKMT2ANPC1RAB9A
SCHEMBL65696 0.83 ALDH1A1 (0.71) ALDH1A1MAPTKMT2ANPC1RAB9A
SCHEMBL17559372 0.83 HPGD (0.61) ALDH1A1KMT2ATSHRCYP1A2HPGD
SCHEMBL2723301 0.83 MAPT (0.58) ALDH1A1MAPTKMT2ARAB9ATSHR
SCHEMBL7379091 0.83 ALDH1A1 (0.51) ALDH1A1MAPTKMT2AHTTSMN1; SMN2
SCHEMBL20897465 0.83 ALDH1A1 (0.71) ALDH1A1MAPTKMT2ANPC1RAB9A
SCHEMBL2951325 0.83 ALDH1A1 (0.71) ALDH1A1MAPTKMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132431-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-04-25 — — US disclosed
EP-4279476-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-22 — — EP disclosed
US-9688696-B2 Piperidine/piperazine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2017-06-27 — — US disclosed
US-20170029440-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-02-02 — — US disclosed
US-9499567-B2 Piperidine/piperazine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2016-11-22 — — US disclosed
US-20150322088-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-11-12 — — US disclosed
EP-2152271-B1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-10-21 — — EP disclosed
US-9120821-B2 Piperidine/piperazine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2015-09-01 — — US disclosed
US-20140350012-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2014-11-27 — — US disclosed
US-8835437-B2 Piperidine/piperazine derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2014-09-16 — — US disclosed
US-20100216809-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2010-08-26 — — US disclosed
EP-2152271-A1 PIPERIDINE/PIPERAZINE DERIVATIVES Janssen Pharmaceutica, N.V. (BE) 2010-02-17 — — EP disclosed
US-20090181966-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-07-16 — — US disclosed
US-7504508-B2 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-03-17 — — US disclosed
WO-2008148840-A1 PIPERIDINE/PIPERAZINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2008-12-11 — — WO disclosed
CN-101018770-A PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARM INC (US) 2007-08-15 — — CN disclosed
EP-1740547-A1 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-01-10 — — EP disclosed
US-20050256158-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. 2005-11-17 — — US disclosed
WO-2005100321-A1 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-10-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216809-A1 PIPERIDINE/PIPERAZINE DERIVATIVES DGAT1, DGAT2, DLAT ALDH1A1 488/4885MAPT 2039/4885KMT2A 825/4885
US-20170029440-A1 PIPERIDINE/PIPERAZINE DERIVATIVES DGAT1, PAOX, DGAT2 ALDH1A1 590/4885MAPT 2270/4885KMT2A 1091/4885
US-20050256158-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases PTGDR2, LTB4R2, CYSLTR2 ALDH1A1 1599/4885MAPT 4208/4885KMT2A 4216/4885
US-20140350012-A1 PIPERIDINE/PIPERAZINE DERIVATIVES DGAT1, PAOX, NNT ALDH1A1 629/4885MAPT 2026/4885KMT2A 1208/4885
US-20090181966-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases PTGDR2, LTB4R2, CYSLTR2 ALDH1A1 1599/4885MAPT 4208/4885KMT2A 4216/4885
US-20150322088-A1 PIPERIDINE/PIPERAZINE DERIVATIVES DGAT1, PAOX, DGAT2 ALDH1A1 590/4885MAPT 2270/4885KMT2A 1091/4885
US-20240132431-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP MGMT, MCL1, FANCF ALDH1A1 446/4885MAPT 4829/4885KMT2A 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.